Potfolio Update: Nanocrine

National Cancer Institute expands Nanocrine collaboration, makes technology commercially available to other cancer researchers

Nanocrine has reached a critical threshold in the adoption of its plasmonic chip technology. A senior researcher at the National Cancer Institute (NCI) is expanding his team’s collaboration with Nanocrine not just for his own research interests, but more importantly to make Nanocrine’s technology commercially available to scores of other cancer biology labs collocated with him at the NCI.

Only Nanocrine’s plasmonic chips could have provided the data that he has found so useful in his lab: the real-time sensing of specific proteins secreted by cancer cells in the tumor micro-environment. This data, together with Nanocrine’s AI/ML software layer, will now provide the critical insights needed for more cancer researchers to deliver breakthrough research and results.

To capitalize on this exciting development, Nanocrine is expanding its bridge round to $950K from $750K. Immediate uses of the funding will be to:

• Hire, train, and support another senior scientist to work directly with the senior researcher in his lab at the NCI ($250K)

• Scale up chip manufacturing with an already-identified, certified facility in California qualified to produce the Nanocrine plasmonic chips at scale for far lower cost ($250K)

The terms for this expanded bridge round continue to remain highly favorable:

• $4.6MM conversion cap 

• 50% warrant coverage upon conversion

• 6% PIK interest

Please contact Tony Coretto for more information or to arrange a meeting with Dr. Patrick Calhoun, Nanocrine's President and Chief Science Officer